Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition

Ann Transl Med. 2020 Apr;8(8):555. doi: 10.21037/atm.2020.01.87.
No abstract available

Publication types

  • Editorial
  • Comment